Characteristics of High Risk People with Cardiovascular Disease in Chinese Rural Areas: Clinical Indictors, Disease Patterns and Drug Treatment

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Wei, Xiaolin ^a   Zou, Guanyang ^b   Yin, Jia ^b   Walley, John ^b   Zhou, Biao ^c   Yu, Yunxian ^c   Tian, Linwei ^a   Chen, Kun ^c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHINESE DRUG; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHINA; CHINESE; COMMUNITY ASSESSMENT; DIABETES MELLITUS; DRUG COST; DRUG USE; FACE TO FACE QUESTIONNAIRE; FEMALE; GENDER; HEALTH SURVEY; HIGH RISK POPULATION; HOLISTIC CARE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PATHOPHYSIOLOGY; PRIMARY MEDICAL CARE; QUESTIONNAIRE; RESIDENTIAL AREA; RURAL POPULATION; SEX RATIO; SMOKING; SYSTOLIC BLOOD PRESSURE;

EID: 84872528217     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054169     Document Type: Article

References (33)

1. National Centre for Cardiovascular Disease (2007) Report on the cardiovascular disease in China 2007. Beijing: Encyclopedia of China Publishing House.
2. Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, et al. (2007) Stroke in China: epidemiology, prevention, and management strategies. Lancet neurology 6: 456-464.
3. WHO (2010) Global status report on on noncommunicable diseases. 1-176.
4. Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, et al. (2003) Proportion of different subtypes of stroke in China. Stroke; a journal of cerebral circulation 34: 2091-2096.
5. National Center for Cardiovascular Dseases C (2011) [Report on cardiovascular diseases in China, 2010]: Encylopedia of China Publishing House.
6. Moran A, Gu D, Zhao D, Coxson P, Wang YC, et al. (2010) Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circulation Cardiovascular Quality And Outcomes 3: 243-252.
7. World Bank (2011) Toward a healthy and harmonious life in China: stemming the rising tide of non-communicable diseases. East Asia and Pacific Region: The World Bank Insititutes.
8. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A, (2005) Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 365: 434-441.
9. Brindle P, eswick A, Fahey T, Ebrahim S, (2006) Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 92: 1752-1759.
10. Barzi F, Patel A, Gu D, Sritara P, Lam TH, et al. (2007) Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health 61: 115-121.
11. Liu J, Hong Y, D'Agostino R, Wu Z, Sun J-y, et al. (2004) Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study. JAMA 291: 2591-2599.
12. Wu Y, Liu X, Li X, Li Y, Zhao L, et al. (2006) Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation 114: 2217-2225.
13. Law MR, Wald NJ, Morris JK, Jordan RE, (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326: 1427.
14. Law MR, Wald NJ, Rudnicka AR, (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326: 1423.
15. Wald NJ, Law MR, (2003) A strategy to reduce cardiovascular disease by more than 80%. BMJ 326: 1419.
16. Wang X, Qin X, Demirtas H, Li J, Mao G, et al. (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369: 1876-1882.
17. Hu DY, Xu XP, (2008) [Prevention of stroke relies on valid control "H" type hypertension]. Zhonghua Nei Ke Za Zhi 47: 976-977.
18. Fan FF, Huo Y, Wang X, Xu X, Wang BY, et al. (2010) Effect of enalapril on plasma homocysteine levels in patients with essential hypertension. J Zhejiang Univ Sci B 11: 583-591.
19. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, et al. (2009) Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 373: 1341-1351.
20. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, et al. (2010) A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract 64: 1220-1227.
21. Chen Z, (2009) Launch of the health-care reform plan in China. The Lancet 373: 1322-1324.
22. NICE (2010) NICE indicator guideline for QOF: Cardiovascular disease- primary care. London: National Institute for Health and Clinical Excellence.
23. NICE (2008) Clinical Guidelines and Evidence Review for Lipid Modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners.
24. Liu L, Wang W, Yao C, China MoH, (2009) China hypertension prevention and control guideline: for primary care. Chinese Journal of Hypertension 18: 11-30.
25. Yang W, Lu J, Weng J, Jia W, Ji L, et al. (2010) Prevalence of Diabetes among Men and Women in China. New England Journal of Medicine 362: 2425-2426.
26. Wu Y, Huxley R, Li L, Vibeke A, Xie G, et al. (2008) Prevalence, Awareness, Treatment, and Control of Hypertension in China: Data from the China National Nutrition and Health Survey 2002. Circulation 118: 2679-2686.
27. Baker S, Priest P, Jackson R, (2000) Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ 320: 680-685.
28. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, et al. (2011) Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. the Lancet 378: 1231-1243.
29. Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, et al. (2005) WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). BullWorld Health Organ 83: 820-829.
30. Tang JL, Wang WZ, An JG, Hu YH, Cheng SH, et al. (2010) How willing are the public to pay for anti-hypertensive drugs for primary prevention of cardiovascular disease: a survey in a Chinese city. Int J Epidemiol 39: 244-254.
31. Volmink J, Garner P (2006) Directly observed therapy for treating tuberculosis. Cochrane Database Of Systematic Reviews 2.
32. Wei X, Walley J, Liang X, Liu F, Zhang X, et al. (2008) Adapting a generic tuberculosis control operational guideline and scaling it up in China: a qualitative case study. BMC Public Health 8: 260 doi:210.1186/1471-2458-1188-1260.
33. Walley J, Graham K, Wei X, Kain K, Weston R, (2012) Getting research into practice: primary care management of noncommunicable diseases in low- and middle-income countries. Bull World Health Organ 90: 402.